
Opinion|Videos|December 8, 2023
Expert Insights in Overcoming Endocrine Resistance for Patients With ER+/HER2- Metastatic Breast Cancer
Author(s)Hope S. Rugo, MD
Expert insights on improving outcomes in ER+/HER2- metastatic breast cancer patients with resistance mutations.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves T-DXd Plus Pertuzumab for HER2-Positive Breast Cancer
2
Teclistamab/Daratumumab Earns FDA Priority Voucher for R/R Myeloma
3
Roxadustat Granted Orphan Drug Designation for Myelodysplastic Syndromes
4
FDA Fast-Tracks Muzastotug Combo in MSS Metastatic Colorectal Cancer
5













































